T-cell vaccination in therapy of multiple sclerosis


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Multiple sclerosis (MS) is a autoimmune disease, due to developing inflammatory focuses of demyelination in the Central Nervous System. T-cell vaccination is a treatment method aimed at stimulating the antiidiotype, immune reactions that are capable of inactivating idiotype, self-reactive lymphocytes. The experimental and clinical data presented in this review indicate that the mechanism of influencing the T-cell vaccination on the MS-causing, autoimmune process includes 4 components: 1) generation of antiidiotypic, CD8+, cytotoxic T-lymphocytes; 2) generation of antiidiotypic CD4+ T-helper cells of 2 and 3 type; 3) stimulation of functionality of CD4+, CD25+ regulatory T cells; and 4) induction of synthesizing antiidiotypic antibodies. The published data suggest expediency of applying T-cell vaccination in the treatment for MS and other autoimmune diseases.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

G. Seledtsova

State Research Institute of Clinical Immunology, Siberian Branch of RAMS

Хат алмасуға жауапты Автор.
Email: vs@online.nsk.su

Laboratory of Cellular Biotechnologies

Ресей, Novosibirsk

I. Ivanova

State Research Institute of Clinical Immunology, Siberian Branch of RAMS

Email: vs@online.nsk.su

Laboratory of Cellular Biotechnologies

Ресей, Novosibirsk

V. Seledtsov

Immanuel Kant State University of Russia

Email: vs@online.nsk.su

Department of Medicine

Ресей, Kaliningrad

Әдебиет тізімі

  1. Giuliani F., Yong V.W. Immune-mediated neurodegeneration and neuroprotection in MS. Int. MS J. 2003; 10: 122—30.
  2. Stbve O., Cravens P.D., EagarT.N. DNA-based vaccines: the future of multiple sclerosis therapy? Expert Rev. Neurother. 2008; 8: 351—60.
  3. Zhang J. T cell vaccination as an immunotherapy for autoimmune diseases. Cell. Mol. Immunol. 2004; 1: 321—7.
  4. Tejada-Simon M.V., Zang Y.C., Yang D. Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int. Immunol. 2000; 12: 1641-50.
  5. Hafler D. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J. Clin. Invest. 1999; 104: 527—9.
  6. Soldan S.S., Berti R., Salem N. Association of human herpes virus 6 CHHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat. Med. 1997; 3: 394—7.
  7. Prinz M., Garbe F., Schmidt H. et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J. Clin. Invest. 2006; 116: 456-64.
  8. Tsunoda I., Tolley N.D., Theil D.J. et al. Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA. Brain Pathol. 1999; 9: 481-93.
  9. Clark D. Human herpesvirus type 6 and multiple sclerosis. Herpes. 2004;11 Suppl 2: 112A-9A.
  10. Lbnemann J.D., KamradtT., Martin R , Mbnz C. Epstein-barr virus: environmental trigger of multiple sclerosis? J. Virol. 2007; 81: 6777—84.
  11. Kebir H., Kreymborg K., Ifergan I. et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007; 13: 1173-5.
  12. Giuliani F., Goodyer C.G., Antel J.P., Yong V.W. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 2003; 171: 368-79.
  13. Huan J., Culbertson N.. Spencer L. et al. Decreased F0XP3 levels in multiple sclerosis patients. J. Neurosci. Res. 2005; 81: 45—52.
  14. Astier A.L., Meiffren G., Freeman S., Hafler D.A. Alterations in CD46-mediated Trl regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 2006:116: 3252-57.
  15. Vandenbark A.A., Finn T., Barnes D. Diminished frequency of IL-10 secreting, TCR peptide-reactive T-cells in multiple sclerosis patients may allow expansion of activated memory T-cells bearing the cognate BV gene. J. Neurosci. Res. 2001; 66: 171—6.
  16. Antel J., Bania M., Noronha A., Neely S. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. J. Immunol. 1986; 137: 3436—9.
  17. Correale J., Farez M., Gilmore W. Vaccines for multiple sclerosis: progress to date. CNS Drugs. 2008; 22: 175—98.
  18. Cohen I.R. Natural Id-anti-ld networks and the immunological homunculus. In: Atlan H., Cohen I.R., editors. Theories of Immune Networks. Berlin: Springer-Verlag; 1986: 6—12.
  19. Hafler D., Cohen I.R.O, Benjamine D., Weiner H.L. T cell vaccination in multiple sclerosis: a preliminary report. Clin. Immunol. Immunopath. 1998; 62: 307-12.
  20. Zhang J., Medaer R., Stinissen P., Hafler D.A., Raus J. MHC restricted clonotypic depletion of human myelin basic protein-reactive T- cells by T cell vaccination. Science 1993; 261: 1451—4.
  21. Zhang J., Raus J. T cell vaccination trial in multiple sclerosis, in T- cell vaccination and autoimmune disease. In: Zhang J., Raus J., editors. Autoimmune disease and T cell vaccination. Austin: Springer-Verlag, Landes Medical Publishers, 1995. p. 135—60.
  22. Correale J., Lund B., McMillan M. et al. T cell vaccination in secondary progressive multiple sclerosis. J. Neuroimmunol. 2000; 107: 130-9.
  23. Zhang J.Z., Rivera V.M., Tejada-Simon M.V. et al. T-cell vaccination in multiple sclerosis: results of a preliminary study. J. Neurol. 2002; 249: 212-8.
  24. Achiron A., Lavie G., Kishner I. et al. T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin. Immunol. 2004; 113: 155-60.
  25. Иванова И.П., Селедцов В.И., Банул Н.В. и др. Получение Т-клеточной вакцины и ее применение для лечения рассеянного склероза. Медицинская иммунология 2005; 7: 27—32.
  26. Иванова И.П., Селедцов В.И., Селедцов Д.В. и др. Индукция антиидиотипического иммунного ответа поликлональной Т-клеточной вакциной у больных рассеянным склерозом. Клеточные технологии в биологии и медицине 2008 [в печати.).
  27. Morgan Е.Е., Nardo C.J., Diveley J.P. et al. Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis. J. Neurosci. Res. 2001; 64: 298—301.
  28. Bourdette D.N., Edmonds E., Smith C. et al. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult. Scler. 2005; 11: 552-61.
  29. Vandenbark A.A., Culbertson N.E., Bartholomew R.M. et al. Therapeutic vaccination with a trivalent T-cell receptor tTCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunol.2008; 123: 66—78.
  30. Zang Y., Hong J., Rivera V. et al. Preferential recognition of hypervariable region sequence by antiidiotypic T cells induced by T-cell vaccination in patients with multiple sclerosis. J. Immunol. 2000; 164: 4011-7.
  31. .Vandenbark A.A. TCR peptide vaccination in multiple sclerosis: Boosting a deficient regulatory network that may involve TCRspecific CD4+CD25+ Treg cells. Curr. Drug Targets Inflamm. Allergy 2005; 4: 85-94.
  32. Hong J., Zang Y.C., Nie H., Zhang J.Z. CD4+ regulatory T-cell responses induced by T cell vaccination in patients with multiple sclerosis. PNAS USA 2006; 103: 5024-9.
  33. Stinissen P., Zhang J., Vandevyver C. et al. T cell responses to activated T cells in multiple sclerosis patients induced by T cell vaccination. J. Neuroimmunol. 1998; 87: 94—104.
  34. Zang Y., Hong J., Tejada-Simon M. Th2 immune regulation induced by T-cell vaccination in patients with multiple sclerosis. Eur. J. Immunol. 2000; 30: 908-13.
  35. Hong J., Zang Y., Rivera V., Zhang J. Reactivity and regulatory properties of anti-idiotypic antibodies induced by T-cell vaccination in patients with multiple sclerosis. J. Immunol. 2000; 165: 6858—64.
  36. Ito K., Tanaka T., Tsutsumi N., Obata F., Kashiwag N. Possible mechanisms of immunotherapy for maintaining pregnancy in recurrent spontaneous aborters: analysis of anti-idiotypic antibodies directed against autologous T-cell receptor. Hum. Reprod. 1999; 14: 650—5.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Eco-Vector, 2023


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>